Literature Search

Liu(X),Yang(Y),Zheng(H),Zhang(Y) Int J Clin Exp Pathol None

...MSH2), MutS homolog 6 (MSH6), and PMS1 homolog 2 (PMS2), in CRC and normal tissues using the Tumor, Normal and Metastati...

Li(B),Wang(B),Song(H),Zheng(H),Wang(Q),Deng(… Ann Med 2026-12-00

...MSH2 predominated in fast-growing grafts, whereas TP53, CHD3 and TET2 were enriched in slow-growing grafts. Slow-growing...

Odintsov(I),Nowak(JA),Baranov(E),Alcindor(T)… Am J Surg Pathol 2026-09-01

...MSH2 , 9 MLH1 , 4 PMS2 , 4 MSH6 , 1 EPCAM ). All tumors evaluated with immunohistochemistry (IHC; n = 36) showed loss of...

Liu(C),Wang(Y) Int J Surg Pathol 2026-06-12

...MSH2, MSH6) expression was evaluated by immunohistochemistry. Pearson's chi-squared test was used to assess the relation...

Apuhan(T),Demir(O),Sagnak Yilmaz(Z),Karaman(… J Cancer Res Clin Oncol 2026-06-13

...MSH2 variant may exhibit heterogeneous tumor-level MMR/MSI phenotypes. Early truncating variants in MSH2 may allow parti...

Ni(C),Xu(J),Pang(Y),Xu(J) Front Immunol None

...MSH2, MSH6, PMS2) and confirmed by next-generation sequencing (NGS). Following disease progression on first-line gemcita...

Xu(C),Gong(Y) Diagn Cytopathol 2026-09-00

...MSH2 (c.14C>A, p.Pro5Gln) with a variant allele frequency (VAF) of 48%, confirming the feasibility of CB as an alternati...

Tsai(AK),Lozada(JR),Kennedy(PR),Moline(D),Pa… Cell Rep Med 2026-07-21

...MSH2 and MSH6 genomic deletions with ultrahigh TMB (>250 mutations/megabase) in whom pembrolizumab resulted in a strikin...

Hu(W),Hu(X),Xie(E),Wang(Y) Front Med (Lausanne) None

...MSH2, MSH6, and PMS2). Patients were classified as dMMR or pMMR. Associations between MMR status and various clinicopath...

Joel(S),Shah(S) BMJ Case Rep 2026-06-29

...MSH2/MSH6, hence confirming the diagnosis of Lynch syndrome. This enabled the decision to treat with immunotherapy for r...